Fasting-Mimicking Diet Reduces HO-1 to Promote T Cell-Mediated Tumor Cytotoxicity

Cancer Cell

Volumn 30, Issue 1, 2016, Pages 136-146

  Di Biase, Stefano ^a   Lee, Changhan ^a   Brandhorst, Sebastian ^a   Manes, Brianna ^a   Buono, Roberta ^a   Cheng, Chia Wei ^a   Cacciottolo, Mafalda ^a   Martin Montalvo, Alejandro ^b   de Cabo, Rafael ^b   Wei, Min ^a   Morgan, Todd E ^a   Longo, Valter D ^a,c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; HEME OXYGENASE 1; HMOX1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CELL KILLING; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DIET RESTRICTION; DOWN REGULATION; FASTING MIMICKING DIET; FEMALE; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC SYSTEM; HUMAN; HUMAN CELL; LONG TERM SURVIVAL; LYMPHOID PROGENITOR CELL; MELANOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; ANIMAL; BREAST NEOPLASMS; CANCER TRANSPLANTATION; CELL PROLIFERATION; CELL SURVIVAL; DIET THERAPY; DISEASE COURSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; IMMUNOLOGY; MCF-7 CELL LINE; METABOLISM; MULTIMODALITY CANCER THERAPY; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DOWN-REGULATION; DOXORUBICIN; FASTING; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEME OXYGENASE-1; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MCF-7 CELLS; MICE; NEOPLASM TRANSPLANTATION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84979761874     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.06.005     Document Type: Article

References (46)

1. Abraham, N.G., Kappas, A., Pharmacological and clinical aspects of heme oxygenase. Pharmacol. Rev. 60 (2008), 79–127.
2. Ahmad, S., Hewett, P.W., Fujisawa, T., Sissaoui, S., Cai, M., Gueron, G., Al-Ani, B., Cudmore, M., Ahmed, S.F., Wong, M.K., et al. Carbon monoxide inhibits sprouting angiogenesis and vascular endothelial growth factor receptor-2 phosphorylation. Thromb. Haemost. 113 (2015), 329–337.
3. Alizadeh, D., Trad, M., Hanke, N.T., Larmonier, C.B., Janikashvili, N., Bonnotte, B., Katsanis, E., Larmonier, N., Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res. 74 (2014), 104–118.
4. Andre, F., Dieci, M.V., Dubsky, P., Sotiriou, C., Curigliano, G., Denkert, C., Loi, S., Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin. Cancer Res. 19 (2013), 28–33.
5. Arinaga, S., Akiyoshi, T., Tsuji, H., Augmentation of the generation of cell-mediated cytotoxicity after a single dose of adriamycin in cancer patients. Cancer Res. 46 (1986), 4213–4216.
6. Balow, J.E., Hurley, D.L., Fauci, A.S., Cyclophosphamide suppression of established cell-mediated immunity. Quantitative vs. qualitative changes in lymphocyte populations. J. Clin. Invest. 56 (1975), 65–70.
7. Bracci, L., Schiavoni, G., Sistigu, A., Belardelli, F., Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 21 (2014), 15–25.
8. Brandhorst, S., Wei, M., Hwang, S., Morgan, T.E., Longo, V.D., Short-term calorie and protein restriction provide partial protection from chemotoxicity but do not delay glioma progression. Exp. Gerontol. 48 (2013), 1120–1128.
9. Brandhorst, S., Choi, I.Y., Wei, M., Cheng, C.W., Sedrakyan, S., Navarrete, G., Dubeau, L., Yap, L.P., Park, R., Vinciguerra, M., et al. A periodic diet that mimics fasting promotes multi-system regeneration, enhanced cognitive performance, and healthspan. Cell Metab. 22 (2015), 86–99.
10. Brusko, T.M., Wasserfall, C.H., Agarwal, A., Kapturczak, M.H., Atkinson, M.A., An integral role for heme oxygenase-1 and carbon monoxide in maintaining peripheral tolerance by CD4+CD25+ regulatory T cells. J. Immunol. 174 (2005), 5181–5186.
11. Burns, W.R., Zhao, Y., Frankel, T.L., Hinrichs, C.S., Zheng, Z., Xu, H., Feldman, S.A., Ferrone, S., Rosenberg, S.A., Morgan, R.A., A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. Cancer Res. 70 (2010), 3027–3033.
12. Carmi, Y., Spitzer, M.H., Linde, I.L., Burt, B.M., Prestwood, T.R., Perlman, N., Davidson, M.G., Kenkel, J.A., Segal, E., Pusapati, G.V., et al. Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity. Nature 521 (2015), 99–104.
13. Casares, N., Pequignot, M.O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 202 (2005), 1691–1701.
14. Chen, G.G., Liu, Z.M., Vlantis, A.C., Tse, G.M., Leung, B.C., van Hasselt, C.A., Heme oxygenase-1 protects against apoptosis induced by tumor necrosis factor-alpha and cycloheximide in papillary thyroid carcinoma cells. J. Cell Biochem. 92 (2004), 1246–1256.
15. Cheng, C.W., Adams, G.B., Perin, L., Wei, M., Zhou, X., Lam, B.S., Da Sacco, S., Mirisola, M., Quinn, D.I., Dorff, T.B., et al. Prolonged fasting reduces IGF-1/PKA to promote hematopoietic-stem-cell-based regeneration and reverse immunosuppression. Cell Stem Cell 14 (2014), 810–823.
16. Choi, B.M., Pae, H.O., Jeong, Y.R., Kim, Y.M., Chung, H.T., Critical role of heme oxygenase-1 in Foxp3-mediated immune suppression. Biochem. Biophys. Res. Commun. 327 (2005), 1066–1071.
17. El Andaloussi, A., Lesniak, M.S., CD4+ CD25+ FoxP3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas. J. Neurooncol. 83 (2007), 145–152.
18. Hirai, K., Sasahira, T., Ohmori, H., Fujii, K., Kuniyasu, H., Inhibition of heme oxygenase-1 by zinc protoporphyrin IX reduces tumor growth of LL/2 lung cancer in C57BL mice. Int. J. Cancer 120 (2007), 500–505.
19. Hsu, F.F., Yeh, C.T., Sun, Y.J., Chiang, M.T., Lan, W.M., Li, F.A., Lee, W.H., Chau, L.Y., Signal peptide peptidase-mediated nuclear localization of heme oxygenase-1 promotes cancer cell proliferation and invasion independent of its enzymatic activity. Oncogene 34 (2015), 2360–2370.
20. Inoue, S., Setoyama, Y., Odaka, A., Doxorubicin treatment induces tumor cell death followed by immunomodulation in a murine neuroblastoma model. Exp. Ther. Med. 7 (2014), 703–708.
21. Issa-Nummer, Y., Darb-Esfahani, S., Loibl, S., Kunz, G., Nekljudova, V., Schrader, I., Sinn, B.V., Ulmer, H.U., Kronenwett, R., Just, M., et al. Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer–a substudy of the neoadjuvant GeparQuinto trial. PLoS One, 8, 2013, e79775.
22. Lee, C., Safdie, F.M., Raffaghello, L., Wei, M., Madia, F., Parrella, E., Hwang, D., Cohen, P., Bianchi, G., Longo, V.D., Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index. Cancer Res. 70 (2010), 1564–1572.
23. Lee, C., Raffaghello, L., Brandhorst, S., Safdie, F.M., Bianchi, G., Martin-Montalvo, A., Pistoia, V., Wei, M., Hwang, S., Merlino, A., et al. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci. Transl. Med., 4, 2012, 124ra127.
24. Liu, Z.M., Chen, G.G., Ng, E.K., Leung, W.K., Sung, J.J., Chung, S.C., Upregulation of heme oxygenase-1 and p21 confers resistance to apoptosis in human gastric cancer cells. Oncogene 23 (2004), 503–513.
25. Liu, Y., Liang, Y., Zheng, T., Yang, G., Zhang, X., Sun, Z., Shi, C., Zhao, S., Inhibition of heme oxygenase-1 enhances anti-cancer effects of arsenic trioxide on glioma cells. J. Neurooncol. 104 (2011), 449–458.
26. Maines, M.D., Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J. 2 (1988), 2557–2568.
27. Maude, S.L., Frey, N., Shaw, P.A., Aplenc, R., Barrett, D.M., Bunin, N.J., Chew, A., Gonzalez, V.E., Zheng, Z., Lacey, S.F., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371 (2014), 1507–1517.
28. Metz, R., Duhadaway, J.B., Rust, S., Munn, D.H., Muller, A.J., Mautino, M., Prendergast, G.C., Zinc protoporphyrin IX stimulates tumor immunity by disrupting the immunosuppressive enzyme indoleamine 2,3-dioxygenase. Mol. Cancer Ther. 9 (2010), 1864–1871.
29. Michaud, M., Martins, I., Sukkurwala, A.Q., Adjemian, S., Ma, Y., Pellegatti, P., Shen, S., Kepp, O., Scoazec, M., Mignot, G., et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 334 (2011), 1573–1577.
30. Orsini, F., Pavelic, Z., Mihich, E., Increased primary cell-mediated immunity in culture subsequent to adriamycin or daunorubicin treatment of spleen donor mice. Cancer Res. 37 (1977), 1719–1726.
31. Otterbein, L.E., Bach, F.H., Alam, J., Soares, M., Tao Lu, H., Wysk, M., Davis, R.J., Flavell, R.A., Choi, A.M., Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat. Med. 6 (2000), 422–428.
32. Pardoll, D.M., Immunology beats cancer: a blueprint for successful translation. Nat. Immunol. 13 (2012), 1129–1132.
33. Raffaghello, L., Lee, C., Safdie, F.M., Wei, M., Madia, F., Bianchi, G., Longo, V.D., Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc. Natl. Acad. Sci. USA 105 (2008), 8215–8220.
34. Rasmussen, L., Arvin, A., Chemotherapy-induced immunosuppression. Environ. Health Perspect. 43 (1982), 21–25.
35. Rock, K.L., Shen, L., Cross-presentation: underlying mechanisms and role in immune surveillance. Immunol. Rev. 207 (2005), 166–183.
36. Safdie, F.M., Dorff, T., Quinn, D., Fontana, L., Wei, M., Lee, C., Cohen, P., Longo, V.D., Fasting and cancer treatment in humans: a case series report. Aging 1 (2009), 988–1007.
37. Suliman, H.B., Carraway, M.S., Ali, A.S., Reynolds, C.M., Welty-Wolf, K.E., Piantadosi, C.A., The CO/HO system reverses inhibition of mitochondrial biogenesis and prevents murine doxorubicin cardiomyopathy. J. Clin. Invest. 117 (2007), 3730–3741.
38. Tertil, M., Golda, S., Skrzypek, K., Florczyk, U., Weglarczyk, K., Kotlinowski, J., Maleszewska, M., Czauderna, S., Pichon, C., Kieda, C., et al. Nrf2-heme oxygenase-1 axis in mucoepidermoid carcinoma of the lung: antitumoral effects associated with down-regulation of matrix metalloproteinases. Free Radic. Biol. Med. 89 (2015), 147–157.
39. Vesely, M.D., Kershaw, M.H., Schreiber, R.D., Smyth, M.J., Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29 (2011), 235–271.
40. Wegiel, B., Gallo, D., Csizmadia, E., Harris, C., Belcher, J., Vercellotti, G.M., Penacho, N., Seth, P., Sukhatme, V., Ahmed, A., et al. Carbon monoxide expedites metabolic exhaustion to inhibit tumor growth. Cancer Res. 73 (2013), 7009–7021.
41. Weinblatt, M.E., Coblyn, J.S., Fox, D.A., Fraser, P.A., Holdsworth, D.E., Glass, D.N., Trentham, D.E., Efficacy of low-dose methotrexate in rheumatoid arthritis. N. Engl. J. Med. 312 (1985), 818–822.
42. Weiner, H.L., Cohen, J.A., Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult. Scler. 8 (2002), 142–154.
43. Wolchok, J.D., Kluger, H., Callahan, M.K., Postow, M.A., Rizvi, N.A., Lesokhin, A.M., Segal, N.H., Ariyan, C.E., Gordon, R.A., Reed, K., et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369 (2013), 122–133.
44. Xia, Z.W., Zhong, W.W., Meyrowitz, J.S., Zhang, Z.L., The role of heme oxygenase-1 in T cell-mediated immunity: the all encompassing enzyme. Curr. Pharm. Des. 14 (2008), 454–464.
45. Zitvogel, L., Tesniere, A., Kroemer, G., Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 6 (2006), 715–727.
46. Zitvogel, L., Apetoh, L., Ghiringhelli, F., Kroemer, G., Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8 (2008), 59–73.